Point-of-care technologies (POC or POCT) are enabling innovative cardiovascular diagnostics that promise to improve patient care across diverse clinical settings. The National Heart, Lung, and Blood Institute convened a working group to discuss POCT in cardiovascular medicine. The multidisciplinary working group, which included clinicians, scientists, engineers, device manufacturers, regulatory officials, and program staff, reviewed the state of the POCT field; discussed opportunities for POCT to improve cardiovascular care, realize the promise of precision medicine, and advance the clinical 
Example 1: rapid evaluation of ER patients with chest pain-"rule out myocardial infarction". In ambulances and ERs, POCT can improve the efficiency of care by enabling rapid assessment and triage of patients with chest discomfort. Cardiac troponin (cTn), a highly sensitive and specific biomarker of myocardial injury, guides triage and management of patients presenting with symptoms suggestive of acute coronary syndrome (9) . ERs already use commercial POC cTn assays, but parallel efforts are exploring whether central laboratory cTn assays can perform serial measurements at progressively shorter intervals to discriminate cardiac from noncardiac causes of chest discomfort and enable rapid patient triage. Historically, stable serial measurements of cTn taken at 6-to 12-h intervals served to "rule out" cardiac injury (10, 11) . More recently, high-sensitivity cTn assays, available only in the central laboratory, permit exclusion of clinically important myocardial injury with high confidence at initial sampling as well as after only 2 serial measurements performed at 1-to 2-h intervals (12) (13) (14) (15) . POC devices that can match this King et al. of microfluidics and dehydrated primers, which measures gene expression fingerprints from circulating cells (37, 38) to provide negative predictive power to limit the need for more elaborate CV testing.
The assay, which in its current instantiation is still far from POC, requires shipment of samples to a central facility. Nonetheless, this early example demonstrates the feasibility of using gene expression fingerprinting as a discriminatory CV biomarker. Table 1 for examples). 
J A C C : B A S I C T O T R A N S L A T I O N A L S C I
E N C E V O L . 1 , N O . 1 -2 , 2 0 1 6 Cardiovascular Point of Care Technologies J A N U A R Y / F E B R U A R Y 2 0 1 6 : 7 3 -8
